Regeneron/$REGN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Regeneron
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
Ticker
$REGN
Sector
Primary listing
Employees
15,182
Headquarters
Website
Regeneron Metrics
BasicAdvanced
$59B
14.45
$39.67
0.32
$2.64
0.61%
Price and volume
Market cap
$59B
Beta
0.32
52-week high
$1,152.01
52-week low
$476.49
Average daily volume
993K
Dividend rate
$2.64
Financial strength
Current ratio
5.391
Quick ratio
4.735
Long term debt to equity
9.035
Total debt to equity
9.035
Dividend payout ratio (TTM)
4.18%
Interest coverage (TTM)
107.05%
Profitability
EBITDA (TTM)
4,428
Gross margin (TTM)
47.28%
Net profit margin (TTM)
31.37%
Operating margin (TTM)
27.56%
Effective tax rate (TTM)
8.54%
Revenue per employee (TTM)
$940,000
Management effectiveness
Return on assets (TTM)
6.59%
Return on equity (TTM)
15.34%
Valuation
Price to earnings (TTM)
14.452
Price to revenue (TTM)
4.31
Price to book
1.99
Price to tangible book (TTM)
2.09
Price to free cash flow (TTM)
17.227
Free cash flow yield (TTM)
5.80%
Free cash flow per share (TTM)
33.283
Dividend yield (TTM)
0.46%
Forward dividend yield
0.61%
Growth
Revenue change (TTM)
5.38%
Earnings per share change (TTM)
5.03%
3-year revenue growth (CAGR)
-0.03%
10-year revenue growth (CAGR)
15.39%
3-year earnings per share growth (CAGR)
-7.44%
10-year earnings per share growth (CAGR)
26.19%
What the Analysts think about Regeneron
Analyst ratings (Buy, Hold, Sell) for Regeneron stock.
Bulls say / Bears say
Regeneron beat Q2 2025 Wall Street forecasts, fueled by strong Dupixent demand as global net sales rose 22% to $4.34 billion compared to estimates of $4.14 billion, confirming its immunology growth momentum.
The U.S. FDA granted accelerated approval to Lynozyfic for relapsed or refractory multiple myeloma in July 2025, the company’s first BCMA×CD3 bispecific antibody approval, significantly expanding its oncology presence into fast-growing hematology markets.
Regeneron reported adjusted Q2 2025 EPS of $12.89, well above analyst projections of $8.44, reflecting robust margin gains and effective cost controls across its core businesses.
EYLEA U.S. net sales dropped 25% year-over-year to $1.15 billion in Q2 2025 due to increased competition from biosimilars and Roche’s Vabysmo, raising worries about the sustainability of Regeneron’s main ophthalmology franchise.
Regeneron missed Q1 2025 earnings forecasts after U.S. Eylea sales declined 26% to $1.04 billion, causing shares to fall nearly 8% and highlighting ongoing challenges in its core eye disease business.
Sanofi stopped supplying Praluent to China because of limited availability, disrupting the rollout of Regeneron’s cholesterol drug in a major pharmaceutical market and signaling potential partnership revenue risks.
Data summarised monthly by Lightyear AI. Last updated on 2 Sept 2025.
Regeneron Financial Performance
Revenues and expenses
Regeneron Earnings Performance
Company profitability
Regeneron News
AllArticlesVideos
Final Trades: ServiceNow, Regeneron, Cisco Systems and Truist Financial
CNBC Television1 week ago
Regeneron's rare immune disorder therapy meets main goal of late-stage trial
Reuters2 weeks ago
These Analysts Increase Their Forecasts On Regeneron Pharmaceuticals After Better-Than-Expected Earnings
Benzinga1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Regeneron stock?
Regeneron (REGN) has a market cap of $59B as of September 08, 2025.
What is the P/E ratio for Regeneron stock?
The price to earnings (P/E) ratio for Regeneron (REGN) stock is 14.45 as of September 08, 2025.
Does Regeneron stock pay dividends?
Yes, the Regeneron (REGN) stock pays dividends to shareholders. As of September 08, 2025, the dividend rate is $2.64 and the yield is 0.61%. Regeneron has a payout ratio of 4.18% on a trailing twelve-month basis.
When is the next Regeneron dividend payment date?
The next Regeneron (REGN) dividend payment date is unconfirmed.
What is the beta indicator for Regeneron?
Regeneron (REGN) has a beta rating of 0.32. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.